This approach would allow us to avoid the undesirable effects on the physiological function of P-gp, providing natural inhibitors in nanosystems targeting cancer cells and resistant leukemic stem cells that overexpress efflux pumps, i.e., using this possibility in AML to target CD33 positive cells [117]. The gene discussed is CD33; the disease is acute myeloid leukemia.